Skip to main content
. 2019 Mar 21;97(5):1996–2008. doi: 10.1093/jas/skz094

Table 5.

Logistic and linear regression models for outcomes associated with passive immunity and ADG in 33 beef calves assisted at birth and medicated with subcutaneous meloxicam (Metacam, 20 mg/mL, 0.5 mg/kg BW, Boehringer Ingelheim, Ingelheim, Germany) or placebo (0.025 mL/kg)

Odds ratio P–value
Failure to stand by 1 h
Medication group
 Placebo Referent
 Meloxicam 1 1.0
Ranch
 A Referent
 B 13.2 0.003
Failure to nurse by 1 h
Medication group
 Placebo Referent
 Meloxicam 0.7 1.0
Failed transfer of passive immunity
Medication group
 Placebo Referent
 Meloxicam 0.2 0.36
Route colostrum consumed
 Nursed from cow Referent
 Tubed or esophageal fed 13.6 0.01
Coefficient (SE) P-value
Serum IgG, g/L
Medication group
 Placebo Referent
 Meloxicam 6.1 (4.4) 0.176
Calving difficulty
 Easy Referent
 Difficult −14.4 (4.6) 0.004
ADG to 7 to 10 d, kg
Medication group
 Placebo Referent
 Meloxicam 0.29 (0.1) 0.05
Ranch
 A Referent
 B 0.4 (0.2) 0.01
Serum IgG concentration, g/L 0.01 (0.005) 0.03
ADG to weaning, kg
Medication group
 Placebo Referent
 Meloxicam 0.05 (0.05) 0.3
Ranch
 A Referent
 B −0.2 (0.06) 0.003
Treatment for disease
 No Referent
  Yes 0.5 (0.3) 0.1
Treatment for disease by Ranch interaction −0.3 (0.1) 0.04
HHS Vulnerability Disclosure